COVID-19 vaccination: an attempt to control the pandemic

Abstract

Background: Since the Severe Acute Respiratory Syndrome Coronavirus-2 was discovered in December 2019, there have been tireless efforts by the medical and scientific community to understand its pathophysiology, treatment, and prevention.
 Discussion: In the last several months, several therapeutic treatments, including a corticosteroid, antiviral drugs, convalescent plasma, and several others, have been tried in the treatment of SARS-CoV-2 with varying results. Pfizer and Moderna COVID-19 vaccines recently received approval for Emergency Use Authorization. Although COVID-19 vaccine is the first hurdle in an attempt to control the pandemic, the following challenges still remain: adequate vaccine doses, issues with mass distribution, global access, proper storage, and sufficient vaccine compliance.
 Summary: Vaccination, in addition to social distancing and wearing facemasks, will likely provide the best way to control the COVID pandemic. Healthcare professionals and government officials will need to address any concern or hesitancy the community has with the COVID vaccine to promote compliance.
 Keywords: coronavirus therapeutics, herd immunity, coronavirus vaccine, vaccine targets, clinical trials

Impact of COVID-19 Vaccination on Pregnant Women

“…In general, herd immunity can be achieved either through vaccination or the natural infection of the majority of the population; thereby, infected or vaccinated individuals gain humoral as well as cellular immunity to combat future infections [ 4 , 5 ]. For deadly diseases such as COVID-19, obtaining herd immunity through natural infection is a setback as it leads to a significant number of deaths in a population [ 13 ]. Hence, the alternative is to vaccinate the general population, which currently serves as the only effective method to ensure a significant decrease in the spread of the disease without placing more lives at risk.…”

COVID-19: Insights into Potential Vaccines

“…On October 12, the company announced that it would pause their clinical trials due to a participant experiencing an unexplained illness. It halted the trials to investigate the reaction's nature to determine whether it was related to the vaccine given [97]. Nevertheless, 11 days after the report, Johnson & Johnson resumed the trials after concluding that the medical event had no clear indication that it was related to the vaccine.…”

Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting

“…Vaccination is perhaps the preferred choice for controlling COVID-19 [ 207 , 208 ]. Epitopes, mRNA, and S protein-RBD structure-based vaccines have been widely proposed and started [ 209 ].…”